Safety of High Doses of Urokinase and Reteplase for Acute Ischemic Stroke

References

1. 1.↵
   1. Nogueira RG,
   2. Liebeskind DS,
   3. Sung G,
   4. et al

   . Predictors of good clinical outcomes, mortality, and successful revascularization in patients with acute ischemic stroke undergoing thrombectomy: pooled analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI trials. Stroke 2009; 40: 3777– 83

   Abstract/FREE Full Text
2. 2.↵
   1. Saqqur M,
   2. Molina CA,
   3. Salam A,
   4. et al

   . Clinical deterioration after intravenous tissue plasminogen activator treatment: a multicenter transcranial Doppler study. Stroke 2007; 38: 69– 74

   Abstract/FREE Full Text
3. 3.↵
   1. Adams HP,
   2. del Zoppo G,
   3. Alberts MJ,
   4. et al

   . Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655– 711

   Abstract/FREE Full Text
4. 4.↵
   1. Shaltoni HM,
   2. Albright KC,
   3. Gonzales NR,
   4. et al

   . Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke? Stroke 2007; 38: 80– 84

   Abstract/FREE Full Text
5. 5.↵
   1. Lee KY,
   2. Kim DI,
   3. Kim SH,
   4. et al

   . Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke. AJNR Am J Neuroradiol 2004; 25: 1470– 75

   Abstract/FREE Full Text
6. 6.↵
   1. Noser EA,
   2. Shaltoni HM,
   3. Hall CA,
   4. et al

   . Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke? Stroke 2005; 36: 292– 96

   Abstract/FREE Full Text
7. 7.↵
   1. Yoon W,
   2. Park MS,
   3. Cho KH.

   . Low-dose intra-arterial urokinase and aggressive mechanical clot disruption for acute ischemic stroke after failure of intravenous thrombolysis. AJNR Am J Neuroradiol 2010; 31: 161– 64

   Abstract/FREE Full Text
8. 8.↵
   1. Qureshi AI,
   2. Siddiqui AM,
   3. Suri MF,
   4. et al

   . Aggressive mechanical clot disruption and low dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 2002; 51: 1319– 27

   PubMedWeb of Science
9. 9.↵
   1. Georgiadis AL,
   2. Memon MZ,
   3. Shah QA,
   4. et al

   . Comparison of partial (.6 mg/kg) versus full-dose (.9 mg/kg) intravenous recombinant tissue plasminogen activator followed by endovascular treatment for acute ischemic stroke: a meta-analysis. J Neuroimaging 2009; Epub ahead of print
10. 10.↵
    1. Sugg RM,
    2. Noser EA,
    3. Shaltoni HM,
    4. et al

    . Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke. AJNR Am J Neuroradiol 2006; 27: 769– 73

    Abstract/FREE Full Text
11. 11.↵
    1. Lin R,
    2. Vora N,
    3. Zaidi S,
    4. et al

    . Mechanical approaches combined with intra-arterial pharmacologic therapy are associated with higher recanalization rates than either intervention alone in revascularization of acute carotid terminus occlusion. Stroke 2009; 40: 2092– 97

    Abstract/FREE Full Text
12. 12.↵
    1. Tirschwell DL,
    2. Coplin WM,
    3. Becker KJ,
    4. et al

    . Intra-arterial urokinase for acute ischemic stroke: factors associated with complications. Neurology 2001; 57: 1100– 03

    Abstract/FREE Full Text
13. 13.↵
    1. Qureshi AI,
    2. Suri MF,
    3. Shatla AA,
    4. et al

    . Intraarterial recombinant tissue plasminogen activator for acute ischemic stroke: an accelerating dose regimen. Neurosurgery 2000; 47: 473– 76

    PubMed
14. 14.↵
    1. Vora NA,
    2. Gupta R,
    3. Thomas AJ,
    4. et al

    . Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke. AJNR Am J Neuroradiol 2007; 28: 1391– 94

    Abstract/FREE Full Text
15. 15.↵
    1. Soares BP,
    2. Chien JD,
    3. Wintermark M

    . MR and CT monitoring of recanalization, reperfusion, and penumbra salvage: everything that recanalizes does not necessarily reperfuse! Stroke 2009; 40: S24– 27

    Abstract/FREE Full Text
16. 16.↵
    1. Grunwald MR,
    2. Hofmann LV

    . Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol 2004; 15: 347– 52

    PubMedWeb of Science
17. 17.↵
    1. Robertson I,
    2. Kessel DO,
    3. Berridge DC

    . Fibrinolytic agents for peripheral artery occlusion. Cochrane Database Syst Rev 2010; 3: CD001099

    PubMed
18. 18.↵
    1. Ogawa A,
    2. Mori E,
    3. Minematsu K,
    4. et al

    . Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007; 38: 2633– 39

    Abstract/FREE Full Text
19. 19.↵
    1. Mori E,
    2. Tabuchi M,
    3. Yoshida T,
    4. et al

    . Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988; 19: 802– 12

    Abstract/FREE Full Text
20. 20.↵
    1. Khatri P,
    2. Hill MD,
    3. Palesch YY,
    4. et al

    . Methodology of the Interventional Management of Stroke III trial. Int J Stroke 2008; 3: 130– 37

    CrossRefPubMedWeb of Science
21. 21.↵
    MR and recanalization of stroke clots using embolectomy (MR RESCUE). http://www.clinicaltrials.gov/ct2/show/NCT00389467?term=MR+RESCUE+TRIAL&rank=1. Accessed July 1, 2009